Tag «ルテチウム(177Lu)ビピボチドテトラキセタン»

Lutetium Lu 177 vipivotide tetraxetan

It’s only fair to share… Lutetium Lu 177 vipivotide tetraxetan FDA APPROVED 2022/3/23, Pluvicto To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies Formula C49H65N9O16. Lu. 3H CAS 1703749-62-5 Mol weight 1214.0819 Antineoplastic, Radioactive agent   Disease Prostate cancer (PSMA positive) ルテチウム(177Lu)ビピボチドテトラキセタン; UNII-G6UF363ECX, WHO 11429 G6UF363ECX 177Lu-Psma-617 Vipivotide tetraxetan Lu-177 177Lu-Labeled PSMA-617 2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) (177Lu)Lutetium 2,2′,2′‘-[10-(2-{[(trans-4-{[(2S)-1-{[(5S)-5-carboxy-5-({[(1S)-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]amino}-3-(2-naphthyl)-1-oxo-2-propanyl]carbamoyl}cyclohexyl)methyl]amino}-2- oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate …